Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6090 Combination Therapy in Hepatocellular Carcinoma
NCT07761286Phase 2Not yet recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Sep 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in hepatocellular carcinoma (HCC), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07761286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07761286.